Anavex Life Sciences Corp. (NASDAQ:AVXL) received a $15.00 price objective from investment analysts at Maxim Group in a research report issued on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target would indicate a potential upside of 275.94% from the company’s current price.

Several other analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Wednesday, April 12th. Noble Financial restated a “buy” rating on shares of Anavex Life Sciences Corp. in a research report on Sunday, April 9th. Finally, ValuEngine downgraded shares of Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating in a research report on Friday, June 30th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Anavex Life Sciences Corp. currently has an average rating of “Buy” and an average price target of $11.94.

Anavex Life Sciences Corp. (AVXL) traded down 0.877% on Monday, reaching $3.955. 125,204 shares of the company traded hands. Anavex Life Sciences Corp. has a 12 month low of $2.43 and a 12 month high of $6.64. The company has a 50-day moving average price of $5.12 and a 200-day moving average price of $5.47. The company’s market capitalization is $163.64 million.

COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/07/maxim-group-analysts-give-anavex-life-sciences-corp-avxl-a-15-00-price-target.html.

Several hedge funds have recently added to or reduced their stakes in AVXL. Park West Asset Management LLC raised its stake in Anavex Life Sciences Corp. by 97.5% in the first quarter. Park West Asset Management LLC now owns 2,962,090 shares of the biotechnology company’s stock worth $17,002,000 after buying an additional 1,462,090 shares in the last quarter. Vanguard Group Inc. raised its stake in Anavex Life Sciences Corp. by 13.1% in the first quarter. Vanguard Group Inc. now owns 1,485,681 shares of the biotechnology company’s stock worth $8,528,000 after buying an additional 171,577 shares in the last quarter. State Street Corp raised its stake in Anavex Life Sciences Corp. by 27.2% in the fourth quarter. State Street Corp now owns 391,065 shares of the biotechnology company’s stock worth $1,549,000 after buying an additional 83,716 shares in the last quarter. Edge Wealth Management LLC bought a new stake in Anavex Life Sciences Corp. during the first quarter worth $230,000. Finally, Geode Capital Management LLC raised its stake in Anavex Life Sciences Corp. by 16.8% in the first quarter. Geode Capital Management LLC now owns 276,974 shares of the biotechnology company’s stock worth $1,589,000 after buying an additional 39,934 shares in the last quarter. Institutional investors own 22.88% of the company’s stock.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.